
    
      This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell
      function, as well as glycemic control and inflammatory markers in newly diagnosed type 2
      diabetic patients on two different treatment regimens: insulin and metformin versus
      glyburide, metformin and pioglitazone.
    
  